SrasV1, PascalFrancis, Corpus, bibRecord, 000322

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')2 in macaques

Identifieur interne : 000322 ( PascalFrancis/Corpus ); précédent : 000321; suivant : 000323

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')2 in macaques

Auteurs : YUNSHENG XU ; ZHENGCAI JIA ; LIYUN ZHOU ; LI WANG ; JINTAO LI ; YUNFEI LIANG ; TINGTING ZHAO ; BING NI ; YUZHANG WU

Source :

International immunopharmacology [ 1567-5769 ] ; 2007.

RBID : Pascal:08-0012795

Descripteurs français

Pascal (Inist)
- Evaluation, Toxicité, Sécurité, Immunogénicité, Réponse immune, Pharmacocinétique, Coronavirus, Syndrome respiratoire aigu sévère, Primates, Pharmacologie.

English descriptors

KwdEn :
- Coronavirus, Evaluation, Immune response, Immunogenicity, Pharmacokinetics, Pharmacology, Primates, Safety, Severe acute respiratory syndrome, Toxicity.

Abstract

To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')₂ requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')₂ fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')₂ or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')₂ in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')₂. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')₂ indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1567-5769`
A03		`1`		`@0 Int. immunopharmacol.`
A05				`@2 7`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')₂ in macaques`
A11	`01`	`1`		`@1 YUNSHENG XU`
A11	`02`	`1`		`@1 ZHENGCAI JIA`
A11	`03`	`1`		`@1 LIYUN ZHOU`
A11	`04`	`1`		`@1 LI WANG`
A11	`05`	`1`		`@1 JINTAO LI`
A11	`06`	`1`		`@1 YUNFEI LIANG`
A11	`07`	`1`		`@1 TINGTING ZHAO`
A11	`08`	`1`		`@1 BING NI`
A11	`09`	`1`		`@1 YUZHANG WU`
A14	`01`			`@1 Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College @2 Wenzhou 325000 @3 CHN @Z 1 aut.`
A14	`02`			`@1 Institute of Immunology, Third Military Medical University @2 Chongqing 400038 @3 CHN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A20				`@1 1834-1840`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27109 @5 354000162128710290`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 08-0012795`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International immunopharmacology`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')₂ requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')₂ fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')₂ or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')₂ in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')₂. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')₂ indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.
C02	`01`	`X`		`@0 002B02`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Evaluation @5 01`
C03	`01`	`X`	`ENG`	`@0 Evaluation @5 01`
C03	`01`	`X`	`SPA`	`@0 Evaluación @5 01`
C03	`02`	`X`	`FRE`	`@0 Toxicité @5 02`
C03	`02`	`X`	`ENG`	`@0 Toxicity @5 02`
C03	`02`	`X`	`SPA`	`@0 Toxicidad @5 02`
C03	`03`	`X`	`FRE`	`@0 Sécurité @5 03`
C03	`03`	`X`	`ENG`	`@0 Safety @5 03`
C03	`03`	`X`	`SPA`	`@0 Seguridad @5 03`
C03	`04`	`X`	`FRE`	`@0 Immunogénicité @5 04`
C03	`04`	`X`	`ENG`	`@0 Immunogenicity @5 04`
C03	`04`	`X`	`SPA`	`@0 Inmunogenicidad @5 04`
C03	`05`	`X`	`FRE`	`@0 Réponse immune @5 05`
C03	`05`	`X`	`ENG`	`@0 Immune response @5 05`
C03	`05`	`X`	`SPA`	`@0 Respuesta inmune @5 05`
C03	`06`	`X`	`FRE`	`@0 Pharmacocinétique @5 06`
C03	`06`	`X`	`ENG`	`@0 Pharmacokinetics @5 06`
C03	`06`	`X`	`SPA`	`@0 Farmacocinética @5 06`
C03	`07`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 07`
C03	`07`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 07`
C03	`07`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 07`
C03	`08`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 08`
C03	`08`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 08`
C03	`08`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 08`
C03	`09`	`X`	`FRE`	`@0 Primates @2 NS @5 09`
C03	`09`	`X`	`ENG`	`@0 Primates @2 NS @5 09`
C03	`09`	`X`	`SPA`	`@0 Primates @2 NS @5 09`
C03	`10`	`X`	`FRE`	`@0 Pharmacologie @5 10`
C03	`10`	`X`	`ENG`	`@0 Pharmacology @5 10`
C03	`10`	`X`	`SPA`	`@0 Farmacología @5 10`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose`
C07	`04`	`X`	`ENG`	`@0 Viral disease`
C07	`04`	`X`	`SPA`	`@0 Virosis`
C07	`05`	`X`	`FRE`	`@0 Infection`
C07	`05`	`X`	`ENG`	`@0 Infection`
C07	`05`	`X`	`SPA`	`@0 Infección`
C07	`06`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`09`	`X`	`FRE`	`@0 Pathologie des poumons @5 38`
C07	`09`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`09`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 009`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0012795 INIST
ET :	Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')₂ in macaques
AU :	YUNSHENG XU; ZHENGCAI JIA; LIYUN ZHOU; LI WANG; JINTAO LI; YUNFEI LIANG; TINGTING ZHAO; BING NI; YUZHANG WU
AF :	Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College/Wenzhou 325000/Chine (1 aut.); Institute of Immunology, Third Military Medical University/Chongqing 400038/Chine (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.)
DT :	Publication en série; Niveau analytique
SO :	International immunopharmacology; ISSN 1567-5769; Pays-Bas; Da. 2007; Vol. 7; No. 13; Pp. 1834-1840; Bibl. 25 ref.
LA :	Anglais
EA :	To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')₂ requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')₂ fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')₂ or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')₂ in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')₂. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')₂ indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.
CC :	002B02; 002B05C02C
FD :	Evaluation; Toxicité; Sécurité; Immunogénicité; Réponse immune; Pharmacocinétique; Coronavirus; Syndrome respiratoire aigu sévère; Primates; Pharmacologie
FG :	Coronaviridae; Nidovirales; Virus; Virose; Infection; Mammalia; Vertebrata; Pathologie de l'appareil respiratoire; Pathologie des poumons
ED :	Evaluation; Toxicity; Safety; Immunogenicity; Immune response; Pharmacokinetics; Coronavirus; Severe acute respiratory syndrome; Primates; Pharmacology
EG :	Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Mammalia; Vertebrata; Respiratory disease; Lung disease
SD :	Evaluación; Toxicidad; Seguridad; Inmunogenicidad; Respuesta inmune; Farmacocinética; Coronavirus; Síndrome respiratorio agudo severo; Primates; Farmacología
LO :	INIST-27109.354000162128710290
ID :	08-0012795

Links to Exploration step

Pascal:08-0012795

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')<sub>2</sub>
 in macaques</title>
<author><name sortKey="Yunsheng Xu" sort="Yunsheng Xu" uniqKey="Yunsheng Xu" last="Yunsheng Xu">YUNSHENG XU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College</s1>
<s2>Wenzhou 325000</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhengcai Jia" sort="Zhengcai Jia" uniqKey="Zhengcai Jia" last="Zhengcai Jia">ZHENGCAI JIA</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liyun Zhou" sort="Liyun Zhou" uniqKey="Liyun Zhou" last="Liyun Zhou">LIYUN ZHOU</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Wang" sort="Li Wang" uniqKey="Li Wang" last="Li Wang">LI WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jintao Li" sort="Jintao Li" uniqKey="Jintao Li" last="Jintao Li">JINTAO LI</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yunfei Liang" sort="Yunfei Liang" uniqKey="Yunfei Liang" last="Yunfei Liang">YUNFEI LIANG</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tingting Zhao" sort="Tingting Zhao" uniqKey="Tingting Zhao" last="Tingting Zhao">TINGTING ZHAO</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bing Ni" sort="Bing Ni" uniqKey="Bing Ni" last="Bing Ni">BING NI</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuzhang Wu" sort="Yuzhang Wu" uniqKey="Yuzhang Wu" last="Yuzhang Wu">YUZHANG WU</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0012795</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0012795 INIST</idno>
<idno type="RBID">Pascal:08-0012795</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000322</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')<sub>2</sub>
 in macaques</title>
<author><name sortKey="Yunsheng Xu" sort="Yunsheng Xu" uniqKey="Yunsheng Xu" last="Yunsheng Xu">YUNSHENG XU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College</s1>
<s2>Wenzhou 325000</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhengcai Jia" sort="Zhengcai Jia" uniqKey="Zhengcai Jia" last="Zhengcai Jia">ZHENGCAI JIA</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liyun Zhou" sort="Liyun Zhou" uniqKey="Liyun Zhou" last="Liyun Zhou">LIYUN ZHOU</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Wang" sort="Li Wang" uniqKey="Li Wang" last="Li Wang">LI WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jintao Li" sort="Jintao Li" uniqKey="Jintao Li" last="Jintao Li">JINTAO LI</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yunfei Liang" sort="Yunfei Liang" uniqKey="Yunfei Liang" last="Yunfei Liang">YUNFEI LIANG</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tingting Zhao" sort="Tingting Zhao" uniqKey="Tingting Zhao" last="Tingting Zhao">TINGTING ZHAO</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bing Ni" sort="Bing Ni" uniqKey="Bing Ni" last="Bing Ni">BING NI</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuzhang Wu" sort="Yuzhang Wu" uniqKey="Yuzhang Wu" last="Yuzhang Wu">YUZHANG WU</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International immunopharmacology</title>
<title level="j" type="abbreviated">Int. immunopharmacol.</title>
<idno type="ISSN">1567-5769</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International immunopharmacology</title>
<title level="j" type="abbreviated">Int. immunopharmacol.</title>
<idno type="ISSN">1567-5769</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Evaluation</term>
<term>Immune response</term>
<term>Immunogenicity</term>
<term>Pharmacokinetics</term>
<term>Pharmacology</term>
<term>Primates</term>
<term>Safety</term>
<term>Severe acute respiratory syndrome</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Evaluation</term>
<term>Toxicité</term>
<term>Sécurité</term>
<term>Immunogénicité</term>
<term>Réponse immune</term>
<term>Pharmacocinétique</term>
<term>Coronavirus</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Primates</term>
<term>Pharmacologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')<sub>2</sub>
 requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')<sub>2</sub>
 fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')<sub>2</sub>
 or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')<sub>2</sub>
 in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')<sub>2</sub>
. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')<sub>2</sub>
 indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1567-5769</s0>
</fA01>
<fA03 i2="1"><s0>Int. immunopharmacol.</s0>
</fA03>
<fA05><s2>7</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')<sub>2</sub>
 in macaques</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>YUNSHENG XU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZHENGCAI JIA</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LIYUN ZHOU</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LI WANG</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JINTAO LI</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>YUNFEI LIANG</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TINGTING ZHAO</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BING NI</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>YUZHANG WU</s1>
</fA11>
<fA14 i1="01"><s1>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College</s1>
<s2>Wenzhou 325000</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Immunology, Third Military Medical University</s1>
<s2>Chongqing 400038</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1834-1840</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27109</s2>
<s5>354000162128710290</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0012795</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International immunopharmacology</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')<sub>2</sub>
 requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')<sub>2</sub>
 fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')<sub>2</sub>
 or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')<sub>2</sub>
 in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')<sub>2</sub>
. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')<sub>2</sub>
 indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Sécurité</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Safety</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Seguridad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Immunogénicité</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Immunogenicity</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inmunogenicidad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Réponse immune</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immune response</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Respuesta inmune</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pharmacocinétique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Pharmacokinetics</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Farmacocinética</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pharmacologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pharmacology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Farmacología</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie des poumons</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0012795 INIST</NO>
<ET>Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')<sub>2</sub>
 in macaques</ET>
<AU>YUNSHENG XU; ZHENGCAI JIA; LIYUN ZHOU; LI WANG; JINTAO LI; YUNFEI LIANG; TINGTING ZHAO; BING NI; YUZHANG WU</AU>
<AF>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College; Institute of venero-dermatology, Wenzhou Medical College/Wenzhou 325000/Chine (1 aut.); Institute of Immunology, Third Military Medical University/Chongqing 400038/Chine (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International immunopharmacology; ISSN 1567-5769; Pays-Bas; Da. 2007; Vol. 7; No. 13; Pp. 1834-1840; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')<sub>2</sub>
 requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')<sub>2</sub>
 fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')<sub>2</sub>
 or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')<sub>2</sub>
 in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')<sub>2</sub>
. The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')<sub>2</sub>
 indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.</EA>
<CC>002B02; 002B05C02C</CC>
<FD>Evaluation; Toxicité; Sécurité; Immunogénicité; Réponse immune; Pharmacocinétique; Coronavirus; Syndrome respiratoire aigu sévère; Primates; Pharmacologie</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Infection; Mammalia; Vertebrata; Pathologie de l'appareil respiratoire; Pathologie des poumons</FG>
<ED>Evaluation; Toxicity; Safety; Immunogenicity; Immune response; Pharmacokinetics; Coronavirus; Severe acute respiratory syndrome; Primates; Pharmacology</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Infection; Mammalia; Vertebrata; Respiratory disease; Lung disease</EG>
<SD>Evaluación; Toxicidad; Seguridad; Inmunogenicidad; Respuesta inmune; Farmacocinética; Coronavirus; Síndrome respiratorio agudo severo; Primates; Farmacología</SD>
<LO>INIST-27109.354000162128710290</LO>
<ID>08-0012795</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000322 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000322 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0012795
   |texte=   Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')2 in macaques
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')2 in macaques

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')2 in macaques

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri